Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer

Stopped early · Phase 1

Conditions studied: Prostate Cancer

In brief

RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nordihydroguaiaretic acid in treating patients with nonmetastatic relapsed prostate cancer.

Key facts

Study ID

NCT00313534

Run by

University of California, San Francisco

People needed

15

Starts

2005-06-01

Expected to finish

2006-10-01

Last updated by the study team

2012-10-11

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• UCSF Comprehensive Cancer Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.